Solid Tumors

(ST005) More accurate measures of disease burden: A strategy for absolute quantification of plasma biomarker levels reduces interference from wild type DNA

(ST006) Pharmacogenomic Testing and Somatic Next Generation Sequencing of Patients with Advanced Solid Tumors

(ST007) Non-V600 BRAF mutated melanomas have immune microenvironments primed for immune checkpoint inhibitor response

(ST008) Enhancing Clinical Utilities of Liquid Biopsy Genomic Testing with Magnetic Nanoparticle Capture Enabled NGS and Multiomics Assays

(ST009) Clinical RNA Panel Detects High Expression of Genes Associated with Small Cell Lung Cancer Subtypes

(ST010) Tumor associated neutrophils and exhausted T cells promote breast cancer lung metastasis upon loss of BRD7

(ST011) LAG-3 expression by RNA next-generation sequencing: Comparison with LAG-3 immunohistochemistry in melanoma

(ST012) DNA damage response gene expression profile distinguishes poor-acting IDH-mutant gliomas with shared methylome signatures.

(ST013) Examining Rare Genitourinary Cancers for Genetic Biomarkers to Explore Potential Targeted Therapy Options

(ST014) Microtissues – A New Way to Understand Tumor Microenvironment

(ST015) Evaluation of Homologous Repair Deficiency status in ovarian carcinoma using in house next generation sequencing panels

(ST016) Immune cell subtyping in Indian Triple-negative breast cancer tumor microenvironment with variable treatment response

(ST017) 3D genomics identify alternate mechanisms of homologous recombination deficiency in uterine sarcoma

(ST018) Enhancing Fusion Oncogene Detection in Driver Negative Pancreaticobiliary Carcinomas, a Single Institution Experience

(ST019) UriFind® Assay Facilitates the Management of Urothelial Carcinoma in a Large-scale Multicenter Prospective Cohort

(ST020) CRISPR-Cas9 Targeting of Somatic Mutations Selectively Kills Cancer Cells

(ST021) Impact of EWSR1 gene rearrangement testing on diagnosis of a wide range of solid tumours

(ST022) Dissecting genomic heterogeneity in glioblastoma by spatial transcriptomic profiling

(ST023) Optimization of Comprehensive Genomic Profiling of Circulating and Solid Tumor DNA to Achieve High Concordance Among Diverse Cancer Types

(ST024) Performance of a Rapid Digital PCR Test for the Detection of Actionable NSCLC Variants Tested at the University of Minnesota-ARDL

(ST025) Evaluation of ctDNA from Early and Advanced Stage NSCLC Specimens for Prevalence of Four Major Gene Mutation Classes

(ST026) Evaluation of the Idylla Rapid IDH1/2 Mutation Assay in FFPE glioma samples

(ST027) Clinical Validation Study of a 505-Gene Panel for Variant Detection in Diverse Solid Tumor Types

(ST028) CDH1 is an Uncommon but Recurrent Tumor Suppressor Gene Mutated in Advanced Prostate Cancer

(ST029) Automation of the Pillar Biosciences oncoReveal Solid Tumor 22 gene panel (ORST22) on the Biomek NGeniuS Next Generation Library Prep System

(ST030) Mutational Signature Analysis by SigMa Across Major Cancer Subtypes Reveals Previously Undescribed Associations

(ST031) Pillar Biosciences oncoReveal methylQuant panels: accurate and easy-to-use methylation NGS assays leveraging SLIMamp technology

(ST032) Large-Scale Comparative Analysis of Gene Fusion Detection across Solid Tumors Using AMP™ and Amplicon-Based Assays

(ST033) Optimizing Read Depth of Real-World Sequencing Data in a Clinical Setting

(ST034) Spectrum of BRCA mutations in Hereditary Breast and Ovarian cancer (HBOC) within the Indian context.

(ST035) Robust low frequency somatic variant detection in cfDNA using a SLIMamp® based liquid biopsy assay

(ST036) Matched fresh frozen and FFPE patient tissues reveal the enhanced sensitivity and data quality of a novel DNA library prep method

(ST037) Dideoxy Sequencing Enhances Detection of KIT Variants in GISTs Initially Evaluated by NGS Hotspot Panels

(ST038) Tumor Diagnosis Re-Classification Based on Comprehensive Molecular Profiling Results Helps Guide Precision Medicine Strategy for Cancer Patients

(ST039) CinCSeq: A Targeted Next Generation Sequencing (NGS) Assay for Comprehensive Management of Pediatric, adolescent, and Young Adult (AYA) Tumors

(ST040) HER2 Expression in Gastrointestinal Malignancies and Correlation with Next Generation Sequencing Results

(ST041) oncoReveal Fusion LBx: Single-tube multiplexed PCR-based NGS assay for detection of multiple gene fusions from cell free RNA

(ST042) Preanalytical Nucleic Acid Assessment for Solid Tumor Genomic Profiling

(ST043) Characterizing Intraprimary Tumor Genetic Heterogeneity in Colorectal Carcinoma with Multiple Driver Alterations

(ST044) Comparison of Microsatellite Instability Assays by Conventional PCR and Next Generation Sequencing

(ST045) Exploration of Ultra-Short Cell-Free DNA In Differentiating Benign and Malignant Ovarian Tumors

(ST046) A Real-time PCR Assay for Identifying ESR1, PGR, ERBB2, MKI67 and a Novel Proliferative Signature in Core Needle Biopsies and Resected Tissue from Patients with Invasive Breast Cancer

(ST047) Enhancing HER2 Evaluation: Correlation between APIS Breast Cancer Subtyping Kit and IHC/ISH for Accurate HER2 Quantification

(ST048) The Design and Development of the APIS ESR1 Mutations Kit to Detect Eleven Mutations Relevant to Acquired Endocrine Therapy Resistance.

(ST049) Clinical Validation of CDKN2A/B Deletions Using the TruSight Oncology 500 Assay

(ST050) Genomic Analysis of Circulating Tumour Cells for Guiding Treatment Decisions in Patients with Metastatic Breast Cancer.

(ST051) Clinical Utility of Homologous Recombination Deficiency (HRD) Profiling in Ovarian Cancer - An Indian Experience

(ST052) Comparison of DNA-Based and RNA-Based Next-Generation Sequencing for the Detection of MET Exon 14 Skipping Alterations in Non-Small Cell Lung Cancer

(ST053) Clinical Actionability of Comprehensive Genomic Profiling in Indian Cancers

(ST054) Embracing the Power of Exome Sequencing for Clinical Somatic Variant Testing of Solid Tumors

(ST055) Cell Cycle Regulators Across Solid Tumors

(ST056) NTRK Fusions and Concomitant Immune and Genomic Landscape Detected by DNA and RNA NGS in a Large Healthcare System

(ST057) Orthogonal Approaches to Validate the Velsera Knowledgebase, a Precision Oncology Knowledgebase that Supports Automated Reporting of Clinically Relevant Somatic Cancer Variants

(ST058) Rapid and Automated Comprehensive Genomic Profiling to Assess Single-gene and Complex Biomarkers Including Genomic Instability

(ST059) Features of Loss-of-Function SYK-Mutated Advanced Melanoma

(ST061) Consistency of Analytic Performance Characteristics and Other Observed Trends from the Validation of Comprehensive Genomic Profiling Laboratory Developed Tests by Diverse Laboratories

(ST062) Identification of Somatic Alterations Enriched in Hispanic Individuals from the Analysis of 1,039 Pediatric Cancers

(ST063) Detecting Structural Variants From FFPE Tissue of Primary CNS Lymphomas Using HiC

(ST064) Clinical Implementation of Matched Tumor/Germline Sequencing Improves Accuracy of Tumor Genomic Profiling and Therapeutic Recommendations

(ST065) Lightning Fast! - Reducing Turn Around Time for MGMT and MLH1 Methylation Assays with the Zymo EZ DNA Methylation-Lightning Kit

(ST066) Comparing Diagnoses from Methylation Array Profiling with Those Generated by Historical Approaches in Archival Pediatric High-Grade Glial Tumors

(ST067) Diagnosis of Oligodendroglioma IDH-Mutant and 1p/19q-Codeleted Using Targeted NGS

(ST068) Primary Intracranial Sarcoma, DICER1-mutant: Three Cases with Molecular Characterization

(ST069) Analytical Validation of a DNA Methylation Biomarker Test for Diagnosis of BE and EAC from Samples Collected Using EsoCheck, a Non-endoscopic Esophageal Cell Collection Device

(ST070) Evaluation of Three Methods for Lynch Syndrome Screening in Patients with Colorectal Cancer

(ST071) A Retrospective Study Comparing Operational Metrics between Different Diagnostic Approaches for Molecular Testing in Lung and Colon Cancers

(ST072) Precision Medicine for Salivary Gland Tumor Patients: Experience Using a Large Next-Generation Sequencing-based RNA Assay to Detect Cancer Associated Gene Alterations at a Multi-Hospital Institution

(ST073) Knowledge of Challenging Tumor Types when Ordering Tumor-Informed Circulating Tumor DNA Testing can Facilitate Appropriate Use of this Testing

(ST074) A blood-based extracellular vesicles DNA methylation signature for colorectal cancer screening

(ST075) Validation of a tumor-informed HLA typing assay to support drug development and clinical decision making

(ST076) Accurate Prediction of 1p19q Co-deletion in Oligodendrogliomas using Comprehensive Genomic Profiling

(ST077) Real-World Evidence Demonstrating the Clinical Performance and Utility of the Labcorp® Plasma Focus™ Liquid Biopsy Test

(ST078) Development of a Novel Exosome-based, Multiplexed RT-qPCR Technology for Rapid and Accurate Detection of Circulating Tumor Acquired Resistance Variants in ESR1 at ≤ 0.1% Frequency

(ST079) Analytical Validation of PGDx elio™ Plasma Focus Dx to Facilitate Precision Oncology Through Decentralized Liquid Biopsy for Solid Tumor Profiling

(ST080) Laboratory Automation of PGDx elio™ Tissue Complete on the Biomek NGeniuS System Enables Accurate and Reproducible Comprehensive Genomic Profiling

(ST081) A rare case of endometrial carcinoma with an FGFR3::TACC3 fusion and an institutional review of FGFR3::TACC3 fusions

(ST082) Validation of Genexus Purification Instrument for DNA and RNA extraction from formalin fixed paraffin embedded tissues for use with patient NGS testing.

(ST083) Innovative NGS-based Approach for Comprehensive Solid Tumor Analysis using Celemics’ CancerScreen Comprehensive Panel

(ST084) Tumor specific somatic variant detection in cfDNA: ability of the AVENIOⓇ Oncology Assay Surveillance Test to detect low level allelic fraction ctDNA variants in cancer patient plasma samples

(ST085) The Idylla™ MSI Test (IVD): An Automated PCR-Based System for the Determination of MSI Status as an Aid for Identification of Probable Lynch Syndrome in Colorectal Cancer Patients

(ST086) Characterization of MET Overexpression (OE) and Impact on Prognosis in a Real-world, Single-Site Cohort of Patients With Nonsquamous Non-small Cell Lung Cancer (NSq NSCLC)

(ST087) Performance Assessment of the Labcorp® Plasma Complete™ Test for Comprehensive Genomic Profiling of Solid Tumors Through Liquid Biopsy

(ST088) Detection of Therapeutically Relevant Mutations in Circulating Tumor DNA at Baseline to Assist in Treatment Decision Making

(ST089) Validation of Entrogen Methylation Sensitive Restriction Enzyme Based qPCR assay to Determine MLH1 Promoter Methylation Status in Colorectal and Endometrial Tumors

(ST090) A Novel Lab Developed Test Simultaneously Assays Heme and Solid Tumors and Shows Good Performance on Degraded Samples at Low Minimum Input

(ST091) Assessment of Tumor Mutation Burden (TMB) Distribution among Different Lineages: Findings from a Single Institution Study

(ST092) Tumor Mutational Burden Quantification Using Small and Moderate Sized Targeted Anchored Multiplex PCR Panels and Next Generation Sequencing

(ST093) Analytical Validation and Performance Characteristics of a 523-gene Next-generation Sequencing Panel for Comprehensive Genomic Profiling of Solid Tumors

(ST094) Microsatellite Instability (MSI) detection with TrueMarkTM MSI Assay

(ST095) Impact of tumor percentage on tumor mutational burden and microsatellite instability measurements from a comprehensive genomic profiling sequencing panel

(ST096) Highly sensitive XNA-based RT-qPCR for detection of ALK, RET, and ROS1 fusions from formalin-fixed and paraffin-embedded lung cancer samples.

(ST097) A quantitative assay for the detection of MGMT methylation in glioblastoma patients

(ST098) Detection of NRG1 Fusion Events in Ovarian, Fallopian Tube, and Primary Peritoneal Carcinomas

(ST099) Multi-omic Characterization and Molecular Profiling of NUT Carcinoma

(ST100) Correlation of Pathogenic Somatic Mutation Presence in Tumor Tissue and Plasma-derived Extracellular Vesicles.

(ST101) Enhancing Breast Cancer Subtyping: APIS Breast Cancer Subtyping Kit Proliferative Signature's Potential for Improved Proliferation Assessment and Recurrence Prediction

(ST102) Rapid and Automated Genomic Profiling of Lung Cancer Solid Tumor and Liquid Biopsy

(ST103) A novel Laboratory Developed Test for identification of key tumor driving cell signaling pathways in breast cancer: ER, AR, PI3K, MAPK, HedgeHog, TGF-β and Notch

(ST104) Moving towards homologous recombination deficiency (HRD) analysis standardization: evaluation of reference materials across leading HRD assays

(ST105) Implementation of TSO500 HT in an Automated Workflow

(ST106) Highly Multiplexed Reference Materials for Analysis of Copy Number Variations

(ST107) Detection of Microsatellite Instability (MSI) Using oncoReveal Core LBx, a Multiplexed, Single Tube, Liquid Biopsy Assay

(ST108) Evaluation and Validation of the TrueMark MSI assay for Microsatellite Instability Status Determination in a Variety of Solid Tumors

(ST109) Validation of the OncoMate™ MSI Dx Analysis System (Promega) on the Applied Biosystems® 3500xL Genetic Analyzer System

(ST110) Improving Cancer Patient Access to Precision Medicine: Maximizing Tissue for Molecular Profiling

(ST111) Analytical performance of TruSight™ Oncology 500 ctDNA v2: Improved sensitivity for small nucleotide variants with reduced DNA input requirements and reduced hands-on time

(ST112) Comprehensive Genomic Profiling of Early Hormone Receptor Positive Breast Cancer Reveals Diverse Genomic Alterations

(ST113) Performance of non-formalin fixed paraffin embedded samples in next generation sequencing panels

(ST114) Validation of Idylla™ BRAF Mutation Assay for the detection of V600E/D and V600K/R/M mutations in patients with Advanced Melanoma.

(ST115) Robust identification of actionable gene fusions using GenMineTOP (RUO), a comprehensive DNA+RNA somatic tissue profiling test

(ST116) The identification of a new FET family fusion candidate in soft tissue sarcoma patients

(ST117) Molecular and Clinical Correlates of MYC Copy Number Gain and MYC Immunohistochemistry in Non-Small Cell Lung Carcinoma

(ST118) The prevalence of subclonal KRAS mutations in colorectal cancer surgical pathology specimens

(ST119) Novel Genomic Structural Variations In Angiosarcomas

(ST120) Comparative Laboratory Performance Evaluation of Pillar Biosciences, ArcherDx, and ThermoFisher Sequencing Chemistries for the Targeted Characterization of CRC & NSCLC samples

(ST121) High degree of NGS concordance in a 9-laboratory study: data from the Genomics Organization for Academic Laboratories

(ST123) CAP/CLIA Validation of a Targeted RNA Pan-Solid Tumor NGS fusion Panel

(ST124) Comprehensive Methylation Profiling to Determine Site of Origin in Mucinous Carcinomas

(ST125) Genomic landscape of ERBB2 alterations in solid tumors without an approved HER2-targeted therapy

(ST126) Clinical implementation of low pass whole genome sequencing in liquid biopsies (LBSeq4Kids) for disease diagnosis and monitoring of childhood solid tumors

(ST127) Identification of a Novel Partner Gene of UPS6 Translocation

(ST128) Molecular diagnosis and treatment guidance of EGFR-positive metastatic non-small cell lung adenocarcinoma from pleural effusion cell-free DNA targeted sequencing

(ST129) Integrating Deep Learning Morphology Profiling and Single Cell RNA-Seq Reveals Tumor Heterogeneity and Enriches Sub-populations

(ST130) Analyzing MGMT promoter methylation using AGENA MassARRAY assay

(ST131) Validation of a Tumor-Only Next-Generation Sequencing Assay for Microsatellite Instability Assessment

(ST132) DICER1 Alterations Identified in a Cohort of 2,236 Solid Tumors of Children and Young Adults

(ST133) Spatial Transcriptomic Evaluation of Lorlatinib-Resistant ALK-Positive Lung Cancer Biopsies

(ST134) Molecular and Demographic Profiles of Patients with Brain Metastases in Non-Small Cell Lung Cancer: A Multi-Site Study

(ST135) Detecting Molecular Residual Disease Through Integrated Tumor Tissue, Germline, and Plasma Whole Genome Sequencing Analyses

(ST136) Secondary KRAS G12C Mutation and Acquired BRAF Inhibitor Resistance in a Patient with Papillary Thyroid Cancer: A Case Report

(ST137) LBSeq4Kids-v2: A pediatric specific targeted sequencing assay for cell-free DNA (cfDNA) profiling of pediatric brain and solid tumors

(ST138) DNA methylation subclassification is the most prognostically relevant biomarker in IDH mutant astrocytomas

(ST139) The Prognostic and Functional Utility of CEACAM6-related Gene Signature in Colorectal Cancer

(ST140) Development of a High resolution melt curve method for a rapid and sensitive detection of IDH1/2 mutation in Glioma

(ST141) Genomic stability of prostate cancers with homologous recombination gene alterations

(ST142) Expression analysis of EMT-related lncRNAs: RMRP, MALAT1 and AGAP2-AS1 in glioma and meningioma brain tumors

(ST143) Comparative Analysis of Chromosomal Microarray (CMA) and 505-gene Next-Generation Sequencing (NGS) Panel for Homologous Recombination Deficiency (HRD) Phenotype Assessment in Solid Tumors

(ST144) Use of Long Mononucleotide Repeat Markers Improves Sensitivity of Microsatellite Instability Testing

(ST145) To UMI or not to UMI: Obtaining robust low-frequency variant identification for liquid biopsy with a SLIMamp-based NGS chemistry without molecular barcoding

(ST146) Microsatellite Instability among Small Intestinal and Appendiceal Adenocarcinomas in the United States

(ST147) Clinical Validation of NxClincal for Investigating Copy Number Alterations (CNA) by Next Generation Sequencing (NGS) in Solid Tumors: A Potential Game Changer.

(ST148) Comparison of ERBB2 and MDM2 Gene Amplification Analysis by Next-Generation Sequencing Copy Number Variation and Fluorescence In Situ Hybridization in Solid Tumors

(ST149) The Utility of DNA Methylation Profiling in Diagnostic Histopathology – an Institutional Experience

(ST150) The Potential Prognostic Impact and Inter-correlations between CTLA-4, PD-1/PD-L1 and CD73/A2AR Immune Checkpoint Molecules in Colorectal Cancer.